A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E’s Vi-capsular polysaccharide-CRM(197) conjugate typhoid vaccine (TyphiBEV(TM)) in healthy infants, children, and adults in comparison with a licensed comparator

The current scenario of typhoid fever warrants early prevention with typhoid conjugate vaccines in susceptible populations to provide lifelong protection. We conducted a multicenter, single-blind, randomized, Phase 2/3 study to assess the immunogenicity and safety of Biological E’s Typhoid Vi-CRM(19...

Descripción completa

Detalles Bibliográficos
Autores principales: Thuluva, Subhash, Paradkar, Vikram, Matur, Ramesh, Turaga, Kishore, GV, Subba Reddy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Licensed Vaccines – Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196756/
https://www.ncbi.nlm.nih.gov/pubmed/35333702
http://dx.doi.org/10.1080/21645515.2022.2043103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196756/
https://www.ncbi.nlm.nih.gov/pubmed/35333702
http://dx.doi.org/10.1080/21645515.2022.2043103

Ejemplares similares